Current atherosclerosis reports
Toth PP.
PMID: 12911842
Curr Atheroscler Rep. 2003 Sep;5(5):339-40. doi: 10.1007/s11883-003-0003-4.
No abstract available.
Cite
Toth PP. Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. Curr Atheroscler Rep. 2003;5(5):339-40doi: 10.1007/s11883-003-0003-4.
Toth, P. P. (2003). Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. Current atherosclerosis reports, 5(5), 339-40. https://doi.org/10.1007/s11883-003-0003-4
Toth, Peter P. "Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy." Current atherosclerosis reports vol. 5,5 (2003): 339-40. doi: https://doi.org/10.1007/s11883-003-0003-4
Toth PP. Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. Curr Atheroscler Rep. 2003 Sep;5(5):339-40. doi: 10.1007/s11883-003-0003-4. PMID: 12911842.
Copy
Download .nbib
Current atherosclerosis reports
Goldstein LB.
PMID: 18173951
Curr Atheroscler Rep. 2007 Oct;9(4):259-60.
No abstract available.
Cite
Goldstein LB. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE trial. Curr Atheroscler Rep. 2007;9(4):259-60
Goldstein, L. B. (2007). Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE trial. Current atherosclerosis reports, 9(4), 259-60.
Goldstein, Larry B. "Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE trial." Current atherosclerosis reports vol. 9,4 (2007): 259-60.
Goldstein LB. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE trial. Curr Atheroscler Rep. 2007 Oct;9(4):259-60. PMID: 18173951.
Copy
Download .nbib
Current atherosclerosis reports
Goldstein LB.
PMID: 18606097
Curr Atheroscler Rep. 2008 Aug;10(4):285-6.
No abstract available.
Cite
Goldstein LB. Anticoagulation for atrial fibrillation in the elderly: part 2. Curr Atheroscler Rep. 2008;10(4):285-6
Goldstein, L. B. (2008). Anticoagulation for atrial fibrillation in the elderly: part 2. Current atherosclerosis reports, 10(4), 285-6.
Goldstein, Larry B. "Anticoagulation for atrial fibrillation in the elderly: part 2." Current atherosclerosis reports vol. 10,4 (2008): 285-6.
Goldstein LB. Anticoagulation for atrial fibrillation in the elderly: part 2. Curr Atheroscler Rep. 2008 Aug;10(4):285-6. PMID: 18606097.
Copy
Download .nbib
Current atherosclerosis reports
Davidson MH.
PMID: 17169245
Curr Atheroscler Rep. 2007 Jan;9(1):46-7.
No abstract available.
Cite
Davidson MH. The ASPEN Study and reduction of cardiovascular events in patients with diabetes. Curr Atheroscler Rep. 2007;9(1):46-7
Davidson, M. H. (2007). The ASPEN Study and reduction of cardiovascular events in patients with diabetes. Current atherosclerosis reports, 9(1), 46-7.
Davidson, Michael H. "The ASPEN Study and reduction of cardiovascular events in patients with diabetes." Current atherosclerosis reports vol. 9,1 (2007): 46-7.
Davidson MH. The ASPEN Study and reduction of cardiovascular events in patients with diabetes. Curr Atheroscler Rep. 2007 Jan;9(1):46-7. PMID: 17169245.
Copy
Download .nbib
Current atherosclerosis reports
Clearfield M.
PMID: 17169240
Curr Atheroscler Rep. 2007 Jan;9(1):8-9.
No abstract available.
Cite
Clearfield M. Efficacy and safety of cholesterol-lowering treatment with statins?. Curr Atheroscler Rep. 2007;9(1):8-9
Clearfield, M. (2007). Efficacy and safety of cholesterol-lowering treatment with statins?. Current atherosclerosis reports, 9(1), 8-9.
Clearfield, Michael. "Efficacy and safety of cholesterol-lowering treatment with statins?." Current atherosclerosis reports vol. 9,1 (2007): 8-9.
Clearfield M. Efficacy and safety of cholesterol-lowering treatment with statins?. Curr Atheroscler Rep. 2007 Jan;9(1):8-9. PMID: 17169240.
Copy
Download .nbib
Current atherosclerosis reports
Stone NJ.
PMID: 18937891
Curr Atheroscler Rep. 2008 Dec;10(6):458-9.
No abstract available.
Cite
Stone NJ. The long-term effect of lifestyle interventions to prevent diabetes. Curr Atheroscler Rep. 2008;10(6):458-9
Stone, N. J. (2008). The long-term effect of lifestyle interventions to prevent diabetes. Current atherosclerosis reports, 10(6), 458-9.
Stone, Neil J. "The long-term effect of lifestyle interventions to prevent diabetes." Current atherosclerosis reports vol. 10,6 (2008): 458-9.
Stone NJ. The long-term effect of lifestyle interventions to prevent diabetes. Curr Atheroscler Rep. 2008 Dec;10(6):458-9. PMID: 18937891.
Copy
Download .nbib
Current atherosclerosis reports
Franz MJ.
PMID: 18937897
Curr Atheroscler Rep. 2008 Dec;10(6):497-502. doi: 10.1007/s11883-008-0077-0.
The clinical application of the glycemic index (GI) to the prevention and treatment of chronic diseases is controversial. No evidence exists for the implementation of low-GI diets for a reduction in coronary heart disease (CHD) mortality, events, or morbidity....
Cite
Franz MJ. Is there a role for the glycemic index in coronary heart disease prevention or treatment?. Curr Atheroscler Rep. 2008;10(6):497-502doi: 10.1007/s11883-008-0077-0.
Franz, M. J. (2008). Is there a role for the glycemic index in coronary heart disease prevention or treatment?. Current atherosclerosis reports, 10(6), 497-502. https://doi.org/10.1007/s11883-008-0077-0
Franz, Marion J. "Is there a role for the glycemic index in coronary heart disease prevention or treatment?." Current atherosclerosis reports vol. 10,6 (2008): 497-502. doi: https://doi.org/10.1007/s11883-008-0077-0
Franz MJ. Is there a role for the glycemic index in coronary heart disease prevention or treatment?. Curr Atheroscler Rep. 2008 Dec;10(6):497-502. doi: 10.1007/s11883-008-0077-0. PMID: 18937897.
Copy
Download .nbib
Current atherosclerosis reports
Toth PP.
PMID: 18001615
Curr Atheroscler Rep. 2007 Nov;9(5):345-6. doi: 10.1007/s11883-007-0043-2.
No abstract available.
Cite
Toth PP. The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary intervention. Curr Atheroscler Rep. 2007;9(5):345-6doi: 10.1007/s11883-007-0043-2.
Toth, P. P. (2007). The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary intervention. Current atherosclerosis reports, 9(5), 345-6. https://doi.org/10.1007/s11883-007-0043-2
Toth, Peter P. "The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary intervention." Current atherosclerosis reports vol. 9,5 (2007): 345-6. doi: https://doi.org/10.1007/s11883-007-0043-2
Toth PP. The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary intervention. Curr Atheroscler Rep. 2007 Nov;9(5):345-6. doi: 10.1007/s11883-007-0043-2. PMID: 18001615.
Copy
Download .nbib
Current atherosclerosis reports
Clearfield M.
PMID: 18383621
Curr Atheroscler Rep. 2008 Feb;10(1):6-7.
No abstract available.
Cite
Clearfield M. Rosuvastatin and carotid intima-media thickness: the METEOR trial. Curr Atheroscler Rep. 2008;10(1):6-7
Clearfield, M. (2008). Rosuvastatin and carotid intima-media thickness: the METEOR trial. Current atherosclerosis reports, 10(1), 6-7.
Clearfield, Michael. "Rosuvastatin and carotid intima-media thickness: the METEOR trial." Current atherosclerosis reports vol. 10,1 (2008): 6-7.
Clearfield M. Rosuvastatin and carotid intima-media thickness: the METEOR trial. Curr Atheroscler Rep. 2008 Feb;10(1):6-7. PMID: 18383621.
Copy
Download .nbib
Current atherosclerosis reports
Rosenson RS.
PMID: 20425257
Curr Atheroscler Rep. 2010 May;12(3):184-6. doi: 10.1007/s11883-010-0103-x.
Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality in industrialized societies [10]. Efforts to reduce cardiovascular events in "high-risk" individuals or recurrent events in patients with established atherosclerotic cardiovascular disease emphasize broad-based implementation of guideline-directed therapeutic...
Cite
Rosenson RS. New technologies personalize diagnostics and therapeutics. Curr Atheroscler Rep. 2010;12(3):184-6doi: 10.1007/s11883-010-0103-x.
Rosenson, R. S. (2010). New technologies personalize diagnostics and therapeutics. Current atherosclerosis reports, 12(3), 184-6. https://doi.org/10.1007/s11883-010-0103-x
Rosenson, Robert S. "New technologies personalize diagnostics and therapeutics." Current atherosclerosis reports vol. 12,3 (2010): 184-6. doi: https://doi.org/10.1007/s11883-010-0103-x
Rosenson RS. New technologies personalize diagnostics and therapeutics. Curr Atheroscler Rep. 2010 May;12(3):184-6. doi: 10.1007/s11883-010-0103-x. PMID: 20425257.
Copy
Download .nbib
Current atherosclerosis reports
Liao JK.
PMID: 19500485
Curr Atheroscler Rep. 2009 Jul;11(4):243-4. doi: 10.1007/s11883-009-0037-3.
No abstract available.
Cite
Liao JK. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Curr Atheroscler Rep. 2009;11(4):243-4doi: 10.1007/s11883-009-0037-3.
Liao, J. K. (2009). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Current atherosclerosis reports, 11(4), 243-4. https://doi.org/10.1007/s11883-009-0037-3
Liao, James K. "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein." Current atherosclerosis reports vol. 11,4 (2009): 243-4. doi: https://doi.org/10.1007/s11883-009-0037-3
Liao JK. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Curr Atheroscler Rep. 2009 Jul;11(4):243-4. doi: 10.1007/s11883-009-0037-3. PMID: 19500485.
Copy
Download .nbib
Current atherosclerosis reports
Liao JK.
PMID: 19500486
Curr Atheroscler Rep. 2009 Jul;11(4):245. doi: 10.1007/s11883-009-0038-2.
No abstract available.
Cite
Liao JK. Genetically elevated C-reactive protein and ischemic vascular disease. Curr Atheroscler Rep. 2009;11(4):245doi: 10.1007/s11883-009-0038-2.
Liao, J. K. (2009). Genetically elevated C-reactive protein and ischemic vascular disease. Current atherosclerosis reports, 11(4), 245. https://doi.org/10.1007/s11883-009-0038-2
Liao, James K. "Genetically elevated C-reactive protein and ischemic vascular disease." Current atherosclerosis reports vol. 11,4 (2009): 245. doi: https://doi.org/10.1007/s11883-009-0038-2
Liao JK. Genetically elevated C-reactive protein and ischemic vascular disease. Curr Atheroscler Rep. 2009 Jul;11(4):245. doi: 10.1007/s11883-009-0038-2. PMID: 19500486.
Copy
Download .nbib
